Invention Grant
- Patent Title: Combination therapy for a stable and long term engraftment using specific protocols for T/B cell depletion
-
Application No.: US14367923Application Date: 2012-12-20
-
Publication No.: US10434121B2Publication Date: 2019-10-08
- Inventor: Yair Reisner , Esther Bachar-Lustig
- Applicant: Yeda Research and Development Co. Ltd.
- Applicant Address: IL Rehovot
- Assignee: Yeda Research and Development Co. Ltd.
- Current Assignee: Yeda Research and Development Co. Ltd.
- Current Assignee Address: IL Rehovot
- International Application: PCT/IL2012/050541 WO 20121220
- International Announcement: WO2013/093919 WO 20130627
- Main IPC: A61K35/28
- IPC: A61K35/28 ; A61K35/17 ; A61K35/22 ; A61K35/38 ; A61K35/39 ; A61K35/407 ; A61K35/42 ; A61K31/675 ; A61K31/661 ; A61K35/34 ; A61K35/36 ; C12N5/00 ; A61K31/198 ; A61K31/255 ; A61K31/7076 ; A61K39/395 ; A61K39/00 ; A61K35/12

Abstract:
A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoetic cells, wherein the T cell depleted immature hematopoetic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject, and wherein the T cell depleted immature hematopoetic cells are obtained by separating the T cells from the immature hematopoetic cells by magnetic cell sorting, and (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per body weight, thereby treating the subject.
Public/Granted literature
Information query
IPC分类: